EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

The Efficacy of 308‐nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo

Maryam Ghiasi, Ahdie Isazade, Tahereh Marhamati, Vahideh Lajevardi, Safoura Shakoei iD

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70020 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Maryam Ghiasi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Vitiligo, Lasers, Excimer, Bimatoprost, Facial Dermatoses. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Topical bimatoprost 0.03% solution (Excilia, Inoclon, Tehran, Iran) was supplied by Company Inoclon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitiligo is a commonly acquired autoimmune pigmentary disorder. Some patients resist conventional treatments, leading to the search for combination therapies.

Aims

This study aimed to compare the efficacy of 308‐nm excimer laser monotherapy versus combined treatment with topical bimatoprost 0.03% in patients with facial vitiligo. Patients and Methods A single‐blind randomized clinical trial was conducted at Razi Hospital, Tehran, on 38 patients with facial vitiligo who had at least one facial vitiligo patch and had not undergone treatment in the past 3 months. The patients were randomly allocated to either the intervention group ( n = 18) or the control group ( n = 20). Both groups received 308‐nm EL therapy twice weekly for 15 weeks, while the intervention group additionally applied 0.03% bimatoprost solution daily. The patients were visited at the end of every 5 weeks and after the 15th week. Efficacy was evaluated using the scale for improvement assessment (SAI), visual analog scale satisfaction (VASS), and visual analog scale improvement (VASI). Data analysis was performed using the Mann–Whitney and t ‐tests, with a significance level set at p < 0.05.

Results

Of the total patients, 27 (71.05%) were female and 11 (28.95%) were male. The male‐to‐female ratio was 50% in the intervention group and 33.33% in the control group. The mean VASI score, as the primary outcome, showed a significant increase over time in the intervention group ( p ≤ 0.001), increasing from 4.53 to 7.20 (an increase of 2.67 units). Additionally, the intervention had a significant effect on the VASI outcome compared to the control ( p ≤ 0.001; mean difference: 2.55 [1.63 to 3.47]). As the secondary outcomes, the mean VASS and SAI scores significantly decreased over time in the intervention group ( p ≤ 0.05). The intervention also significantly affected the VASS and SAI outcomes compared to the control ( p ≤ 0.001). The side effects of the intervention group were hypertrichosis in three patients and erythema burning in one patient.

Conclusions

Adding bimatoprost 0.03% to the treatment regimen may improve the outcomes of patients with facial vitiligo who are resistant to conventional treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoLasers, ExcimerBimatoprostFacial DermatosesLow-Level Light TherapyHumansFemaleMaleAdultSingle-Blind MethodTreatment OutcomeMiddle AgedCombined Modality TherapyYoung AdultPatient SatisfactionAdministration, CutaneousFaceAdolescent

Stichwörter der Autor:innen

Bimatoprostexcimer laservitiligo

Substanzen

Bimatoprost

Autor:innen und Institutionen

  • Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Dermatology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.

ORCID-Profile: Safoura Shakoei

Förderung

  • Topical bimatoprost 0.03% solution (Excilia, Inoclon, Tehran, Iran) was supplied by Company Inoclon

Zitieren

APA

Ghiasi, M., Isazade, A., Marhamati, T., Lajevardi, V., & Shakoei, S. (2025). The Efficacy of 308‐nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70020

Vancouver

Ghiasi M, Isazade A, Marhamati T, Lajevardi V, Shakoei S. The Efficacy of 308‐nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70020

BibTeX
@article{Ghiasi2025,
  author = {Ghiasi, Maryam and Isazade, Ahdie and Marhamati, Tahereh and Lajevardi, Vahideh and Shakoei, Safoura},
  title = {The Efficacy of 308‐nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70020}
}
Kostenlos starten →